Quick Answer
Vitamin D Immune Support Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Objective This umbrella review aimed to evaluate the efficacy and safety of vitamin D supplementation as an adjunctive treatment for asthma and to assess the credibility of the existing evidence.
Key Takeaways
- 01Objective This umbrella review aimed to evaluate the efficacy and safety of vitamin D supplementation as an adjunctive treatment for asthma and to assess the credibility of the existing evidence. [Liu Y (2026)]
- 02We assessed methodological quality, risk of bias, reporting quality, certainty of evidence, and overlap among primary studies using standard appraisal tools. [Liu Y (2026)]
- 03Vitamin D supplementation was associated with a lower risk of asthma exacerbations, but its effects on asthma control, lung function, and inflammatory outcomes were limited or inconsistent. [Liu Y (2026)]
- 04Background Asthma is a common chronic airway disease that can cause recurrent symptoms, acute exacerbations, impaired quality of life, and substantial healthcare burden. [Liu Y (2026)]
The current Migaku evidence database contains 2 reusable source documents for Vitamin D Immune Support Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Objective This umbrella review aimed to evaluate the efficacy and safety of vitamin D supplementation as an adjunctive treatment for asthma and to assess the credibility of the existing evidence. [Liu Y (2026); evidence level 1]
- We assessed methodological quality, risk of bias, reporting quality, certainty of evidence, and overlap among primary studies using standard appraisal tools. [Liu Y (2026); evidence level 1]
- Vitamin D supplementation was associated with a lower risk of asthma exacerbations, but its effects on asthma control, lung function, and inflammatory outcomes were limited or inconsistent. [Liu Y (2026); evidence level 1]
- Background Asthma is a common chronic airway disease that can cause recurrent symptoms, acute exacerbations, impaired quality of life, and substantial healthcare burden. [Liu Y (2026); evidence level 1]
- Risk of bias was assessed using the Cochrane ROB2 tool, and meta-analysis was conducted using a random-effects model. [Li D (2026); evidence level 1]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources